NYU Langone Comprehensive Epilepsy Center

The trials here

What the 4 trials at this site are about, from their registry records.

Conditions

• Epilepsy4 trials

Phase

• Phase 22 trials
• Phase 32 trials

Status

• Recruiting2 trials
• Completed1 trial
• Terminated1 trial

Lead sponsor

• Rapport Therapeutics Inc.2 trials
• Eisai Inc.1 trial
• Neurona Therapeutics1 trial

Running trials

• Recruiting

  A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures

  NCT07219407· Phase 2· Rapport Therapeutics Inc.· Source

  Contact: Daniela Moreno

• Recruiting

  Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))

  NCT05135091· Phase 3· Neurona Therapeutics· Source

  Contact: Jack C Carter, BS

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Epilepsy2 recruiting

Closed trials

• Completed

  Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy

  NCT06377930· Phase 2· Rapport Therapeutics Inc.· Source

• Terminated

  A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome

  NCT04572243· Phase 3· Eisai Inc.· Source